Available Until 8/31/2026
View Cart

Gene Therapy in Sickle Cell Disease

Planned in cooperation with the ASHP Section of Specialty Pharmacy Practitioners Educational Steering Committee

ACPE Activity Number: 0204-0000-23-089-H01-P
Release Date:  8/30/2023
Expiration Date: 8/30/2026
Activity Type: Knowledge-based 
CE Credits:  1.0 contact hour, (0.10 CEUs)
Activity Fee: Member – Free / Non-Member – Not Available 

This activity is a recording from a live webinar and those that claim credit for the live webinar should not claim credit for this activity.

Activity Overview 

In this webinar, expert faculty will discuss novel gene therapy treatment options for sickle cell disease. This session will cover current therapies in sickle cell disease, different gene approaches and available evidence to support these therapies, and health economics and cost effectiveness considerations of gene therapy. 

   
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

This activity was planned to meet the educational needs of pharmacists and practitioners working in specialty pharmacy or with patients who have sickle cell disease and of adminisitrative leaders with oversight of these areas.   

After completing this activity, the learner should be able to…

  • Discuss key clinical considerations and therapeutic options, including gene therapy, for patients with sickle cell disease.
  • Identify patient care issues including access to gene therapy and therapeutic outcomes in treatment of sickle cell disease.
  • Describe the health economics and cost effectiveness related to use of gene therapy for sickle cell disease.  

  • Introduction and Announcements 

  • Presentation  

  • Questions, Answers, and Discussion 

Jin Han, PharmD, PhD
Clinical Associate Professor
University of Illinois College of Pharmacy
Clinical Pharmacist, Sickle Cell Disease Clinic
University of Illinois Hospital and Health Sciences System
Chicago, IL 

Anirban Basu, PhD
Stergachis Family Endowed Director and Professor of Health Economics
University of Washington College of Pharmacy
Seattle, WA 98195 

Moderator

Kyle Hansen, PharmD, MS, BCPS, CSP
Pharmacy Manager
Atrium Health Wake Forest
Baptist Medical Center 
Winston-Salem, NC

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

  • No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company. 

This activity consists of recordings of faculty slides presentations, active learning activities, discussion, and handouts. Participants must participate in the activity in its entirety to claim continuing pharmacy education credit online at ASHP Learning Center. Follow the prompts online to complete the evaluation, claim credit and view the statement of credit immediately after completing the activity. 

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.